Serina Therapeutics | 8-K: Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Serina Therapeutics | 10-Q: Q2 2024 Earnings Report
Serina Therapeutics | 8-K: Current report
8-K: Current report
4: Statement of changes in beneficial ownership of securities-Officer Tenjarla Srini
3: Initial statement of beneficial ownership of securities-Officer Tenjarla Srini
8-K: Current report
EFFECT: Others
SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Juvenescence Limited(38.0%),JuvVentures (UK) Limited(37.1%)
Serina Therapeutics | CORRESP: CORRESP
S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
4: Statement of changes in beneficial ownership of securities-Director MINTZ STEVEN
S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
8-K: Current report
4: Statement of changes in beneficial ownership of securities-Director Bailey Gregory
4: Statement of changes in beneficial ownership of securities-Director Bailey Gregory
4: Statement of changes in beneficial ownership of securities-Director Bailey Gregory
4: Statement of changes in beneficial ownership of securities-Director MINTZ STEVEN
4: Statement of changes in beneficial ownership of securities-Director Bailey Gregory
No Data